NCT03867344

Brief Summary

The purpose of this study is to examine the effect of a moderately low blood sugar stress on the nervous system. The investigators hope that information obtained from completing this study will help to reveal information about how a non-psychological stress impacts the parts of the brain that react to stress and the autonomic nervous system. The autonomic nervous system is the part of the nervous system that provides the body with involuntary or automatic control of heart rate, blood pressure, and breathing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 8, 2019

Completed
7 months until next milestone

Study Start

First participant enrolled

October 1, 2019

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

January 5, 2026

Status Verified

December 1, 2025

Enrollment Period

6.3 years

First QC Date

March 4, 2019

Last Update Submit

December 30, 2025

Conditions

Keywords

HypoglycemiaStressBrain

Outcome Measures

Primary Outcomes (2)

  • Effect of physiological stress (hypoglycemia) on brain networks involved in autonomic function

    Functional MRI will be performed following physiological stress (hypoglycemia) or placebo (normoglycemia) and a functional connectivity analysis will be performed on the fMRI data. The outcome will be alterations in neural network connectivity, as measured by changes in Pearson-correlation coefficients among the following brain structures: right anterior insula and anterior cingulate cortex; right anterior insula and hypothalamus; hypothalamus and anterior cingulate cortex; hypothalamus and amygdala; locus coeruleus and hypothalamus.

    Baseline, 8 hours after physiological stress, and 4 days after physiological stress

  • The relationship over time between stress-induced changes in brain networks and stress-induced changes in baroreflex sensitivity

    The stress-induced change in baroreflex sensitivity (msec/mmHg) will be determined. Pearson correlation coefficients (r) between the changes in baroreflex sensitivity and the changes in brain connectivity (right anterior insula and anterior cingulate cortex; hypothalamus and amygdala \[determined for the first outcome above\]) will be calculated and tested for significance.

    Baseline, 8 hours after physiological stress, and 4 days after physiological stress

Study Arms (2)

Hypoglycemia

ACTIVE COMPARATOR

Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.

Other: Hypoglycemic Hyperinsulinemic Clamp

Normoglycemia

PLACEBO COMPARATOR

Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.

Other: Normoglycemic Hyperinsulinemic Clamp

Interventions

Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.

Also known as: Hypoglycemic Hyperinsulinemic Clamp Procedure
Hypoglycemia

Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.

Also known as: Normoglycemic Hyperinsulinemic Clamp Procedure
Normoglycemia

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy volunteers
  • Males and Females age 18 to 45 years
  • BMI 18-35 kg/m2

You may not qualify if:

  • Pregnancy
  • Lactation
  • Menopause
  • Any medical condition
  • Current or prior alcohol or drug abuse
  • Active tobacco use
  • Abnormal ECG
  • In all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded.
  • Use of medications other than thyroid hormone or hormonal birth control
  • Serum potassium \>5.0 mmol/L
  • Estimated GFR \<60 mL/min/1.73 m2
  • Hemoglobin A1c ≥6.5%
  • Patient Health Questionnaire (PHQ9) for depression score ≥15
  • GAD-7 Questionnaire for anxiety score ≥10
  • PTSD Checklist for DSM-5 (PCL-5) score ≥31
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States

Location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Hypoglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Roy Freeman, MD

    Beth Israel Deaconess Medical Center

    PRINCIPAL INVESTIGATOR
  • Gail K Adler, MD, PhD

    Brigham and Women's Hospital

    PRINCIPAL INVESTIGATOR
  • David Borsook, MD, PhD

    Boston Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 4, 2019

First Posted

March 8, 2019

Study Start

October 1, 2019

Primary Completion

December 30, 2025

Study Completion

December 30, 2025

Last Updated

January 5, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

The data collected will comply with the NIH requirements for timely release and data sharing. Data will be shared in the form of publications and presentations in scientific forums. As the NIH has noted, the investigators reserve the right to keep the data restricted in order to perform the initial analyses for this grant proposal and will continue to use the data for further, but not prolonged, exclusive use. Of note, the sharing of this data will be limited by at least the following issues, some unique to this proposal and some not unique. Some of the data obtained in this study is defined to be sensitive in nature, which may restrict its ability to be shared. Data may only be shared with the approval of our IRB and is limited by HIPPA and any other regulations that may be promulgated during the course of this proposal.

Time Frame
Data will be shared after completion of study and initial publications which we anticipate to be within 18 months of the final participant completing the study protocol.
Access Criteria
Access to data must be approved by the IRB at our institution.

Locations